Several lines of evidence support an oncogenic role for OGC in cancer: (i) OGC is upregulated in non-small-cell lung cancer (NSCLC), melanoma [89], hepatocellular carcinoma [90], and in cell line models of these tumors; (ii) loss of function of OGC reduces tumor growth and decreases both the number and overall burden of lung metastases in xenograft mouse models [89,90,91]. Here, SLC25A11 is linked to non-small cell lung carcinoma.